陈红专 教授

1978-1983 浙江医科大学 临床医学专业 获学士学位

1983-1986 上海第二医科大学药理学专业 获硕士学位

1987-1990上海第二医科大学药理学专业获博士学位

1993-1995 法国国立健康与卫生研究院（INSERM）博士后

1998-1999 法国里昂第一大学临床药理学 高级访问学者

代表性文章

1. Lin JY#, Wu Y#, Liang XH, Tang M, Sun X, Lu SX, Jin JM, Guo X, Wang B,Chen HZ*, Zhang WD*,Luan X*. A Self-Assembling LYTAC Mediates CTGF Degradation and Remodels Inflammatory Tumor Microenvironment for Triple-Negative Breast Cancer Therapy.Adv Sci.2025, e2500311. doi: 10.1002/advs.202500311. Online ahead of print.IF:14.3

2. Shi J#, Song C#*, Zhang P, Wang J, Huang W, Yu T, Wei Z, Wang L, Zhao L, ZhangR, Hou L, Zhang Y,Chen H*, Wang H*. Microglial circDlg1 modulatesneuroinflammation by blocking PDE4B ubiquitination-dependent degradationassociated with Alzheimer's disease.Theranostics. 2025 Feb 24;15(8):3401-3423.IF: 12.4

3. Ren M#, Sun X#, Lin J, Kan Y, Lu S, Zhang X, Liang R, Wang B,Chen H*, Wu Y*, Luan X*. Hypoxia-responsive oncolytic conjugate triggers type-II immunogenic cell death for enhanced photodynamic immunotherapy.J Control Release. 2025, 382:113717. doi: 10.1016/j.jconrel.2025.113717. Online ahead of print.IF:10.5.

4. Gao J#, Song Q#, Gu X, Jiang G, Huang J, Tang Y, Yu R, Wang A, Huang Y, ZhengG*,Chen H*, Gao X*. Intracerebral fate of organic and inorganic nanoparticles isdependent on microglial extracellular vesicle function.Nat Nanotechnol. 2024Mar;19(3):376-386.IF: 38.1

5. Huang J#, Fu Y#, Wang A, Shi K, Peng Y, Yi Y, Yu R, Gao J, Feng J, Jiang G,Song Q, Jiang J,Chen H*, Gao X*. Brain Delivery of Protein Therapeutics by CellMatrix-Inspired Biomimetic Nanocarrier.Adv Mater.2024 Aug;36(31):e2405323.IF: 27.4

6. Lu X#, Jin J#, Wu Y#, Lin J, Zhang X, Lu S, Zhang J, Zhang C, Ren M,Chen H*,Zhang W*, Luan X*. Self-assembled PROTACs enable protein degradation to reprogramthe tumor microenvironment for synergistically enhanced colorectal cancerimmunotherapy.Bioact Mater. 2024 Sep 25;43:255-272.IF: 18.0

7. Chen Y#, Zhang C#, Huang Y, Ma Y, Song Q,Chen H*, Jiang G*, Gao X*. Intranasaldrug delivery: The interaction between nanoparticles and the nose-to-brainpathway.Adv Drug Deliv Rev. 2024 Apr;207:115196.IF: 15.2

8. Zhang X#, Wu Y#, Lin J, Lu S, Lu X, Cheng A,Chen H*, Zhang W*, Luan X*. Insightsinto therapeutic peptides in the cancer-immunity cycle: Update and challenges.Acta Pharm Sin B. 2024 Sep;14(9):3818-3833.IF: 14.8

9. Wang C#, Zhang M#, Li S, Gong M, Luo MY, Zhang MC, Zou JH, Shen N, Xu L, LeiHM, Bi L, Zhu L, Wang Z,Chen HZ*, Zhou L*, Shen Y*. A phosphoglycerate mutase 1allosteric inhibitor restrains TAM-mediated colon cancer progression.Acta PharmSin B. 2024 Nov;14(11):4819-4831.IF: 14.8

10. Bian H#, Liang X#, Lu D#, Lin J, Lu X, Jin J, Zhang L, Wu Y*,Chen H*, Zhang W*,Luan X*. In Silico Discovery of Stapled Peptide Inhibitor Targeting theNur77-PPARγ Interaction and Its Anti-Breast-Cancer Efficacy.Adv Sci (Weinh).2024 Jul;11(26):e2308435.IF: 14.3

11. Zhang Y#, Ding X#, Zhang Q, Zeng C,Chen H*, Lu L*. Trichosanthin elicitsantitumor activity via MICU3 mediated mitochondria calcium influx.J Adv Res.2024 Nov 4:S2090-1232(24)00493-4.IF: 11.4

12. Lu J#, Wu K#, Sha X, Lin J,Chen H*, Yu Z*. TRPV1 alleviates APOE4-dependentmicroglial antigen presentation and T cell infiltration in Alzheimer's disease.Transl Neurodegener. 2024 Oct 29;13(1):52.IF: 10.8

13. Song C#, Huang W, Zhang P, Shi J, Yu T, Wang J, Hu Y, Zhao L, Zhang R, WangG, Zhang Y,Chen H*, Wang H*. Critical role of ROCK1 in AD pathogenesis viacontrolling lysosomal biogenesis and acidification.Transl Neurodegener. 2024Nov 4;13(1):54.IF: 10.8

14. Tao L#, Yang G#, Sun T#, Jie Tao, Zhu C, Yu H, Cheng Y, Yang Z, Xu M, Jiang Y,Zhang W, Wang Z, Ma W, Wu L, Xue D, Wang D, Yang W, Zhao Y, Horsefield S, KobeB, Zhang Z, Tang Z, Li Q, Zhai Q, Dooley S, Seki E, Liu P*, Xu J*,Chen H*, Liu C*.Capsaicin receptor TRPV1 maintains quiescence of hepatic stellate cells in theliver via recruitment of SARM1.J Hepatol. 2023 Apr;78(4):805-819.IF: 26.8，入选2023年度中医药十大学术进展。

15. Liang Q#, Gong M#, Zou JH, Luo MY, Jiang LL, Wang C, Shen NX, Zhang MC, Xu L,Lei HM, Zhang KR, Zhang R, Zhuang G, Zhu L,Chen HZ*, Zhou L*, Shen Y*. Aphosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance toEGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lungadenocarcinoma.Drug Resist Updat. 2023 May;68:100957.IF: 15.8

16. Wang D#, Gu X#, Ma X, Chen J, Zhang Q, Yu Z, Li J, Hu M, Tan X, Tang Y, Xu J,Xu M, Song Q, Song H, Jiang G, Tang Z, Gao X*,Chen H*. Nanopolyphenol rejuvenatesmicroglial surveillance of multiple misfolded proteins through metabolicreprogramming.Acta Pharm Sin B. 2023 Feb;13(2):834-851.IF: 14.8

17. Zhou S#, Huang Y#, Chen Y, Liu Y, Xie L, You Y, Tong S, Xu J, Jiang G, Song Q,Mei N, Ma F, Gao X,Chen H*, Chen J*. Reprogramming systemic and local immunefunction to empower immunotherapy against glioblastoma.Nat Commun. 2023 Jan26;14(1):435.IF: 14.7

18. Zhang Q#, Song Q#, Yu R, Wang A, Jiang G, Huang Y, Chen J, Xu J, Wang D,ChenH*, Gao X*. Nano-Brake Halts Mitochondrial Dysfunction Cascade to AlleviateNeuropathology and Rescue Alzheimer's Cognitive Deficits.Adv Sci (Weinh). 2023Mar;10(7):e2204596.IF: 14.3

19. Li JB#, Hu XY#, Chen MW, Xiong CH, Zhao N, Ge YH, Wang H, Gao XL, Xu NJ, ZhaoLX, Yu ZH,Chen HZ*, Qiu Y*. p85S6K sustains synaptic GluA1 to amelioratecognitive deficits in Alzheimer's disease.Transl Neurodegener. 2023 Jan9;12(1):1.IF: 10.8

20. Jiang G#, Wei C#, Chen Y, Lyu Y, Huang J,Chen H*, Gao X*. Targeted drugdelivery system inspired by macropinocytosis.J Control Release. 2023Jul;359:302-314.IF: 10.5

21. Liu Y#, Zhang N#, Xie C, Jiang Y, Qin Y, Zhou L, Fan Y, Ren L, Yin C, Yang H,Xie W, Zhai Q, Li G,Chen H*, Chen X*. Evolution of drug regulations andregulatory innovation for anticancer drugs in China.Acta Pharm Sin B. 2022Dec;12(12):4365-4377.IF: 14.8

22. Tang Y#, Gao J#, Wang T, Zhang Q, Wang A, Huang M, Yu R,Chen H*, Gao X*. Theeffect of drug loading and multiple administration on the protein coronaformation and brain delivery property of PEG-PLA nanoparticles.Acta Pharm SinB. 2022 Apr;12(4):2043-2056.IF: 14.8

23. Yu Y#, Zhang Z#, Dong X, Yang R, Duan Z, Xiang Z, Li J, Li G, Yan F, Xue H,Jiao D, Lu J, Lu H, Zhang W, Wei Y, Fan S, Li J, Jia J, Zhang J, Ji J, Liu P, LuH, Zhao H, Chen S, Wei C,Chen H*, Zhu Z*. Pangenomic analysis of Chinese gastriccancer.Nat Commun. 2022 Sep 15;13(1):5412.IF: 14.7

24. Song C#, Zhang Y#, Huang W, Shi J, Huang Q, Jiang M, Qiu Y, Wang T,Chen H*,Wang H*. Circular RNA Cwc27 contributes to Alzheimer's disease pathogenesis byrepressing Pur-α activity.Cell Death Differ.2022 Feb;29(2):393-406.IF: 13.7

25. Mu Y#, Zhang L#, Hu J, Zhou J, Lin HW, He C,Chen HZ*, Zhang L*. A fungaldioxygenase CcTet serves as a eukaryotic 6mA demethylase on duplex DNA.Nat ChemBiol. 2022 Jul;18(7):733-741.IF: 13.0

26. Luo MY#, Zhou Y#, Gu WM, Wang C, Shen NX, Dong JK, Lei HM, Tang YB, Liang Q,Zou JH, Xu L, Ma P, Zhuang G, Bi L, Xu L, Zhu L,Chen HZ*, Shen Y*. Metabolic andNonmetabolic Functions of PSAT1 Coordinate Signaling Cascades to Confer EGFRInhibitor Resistance and Drive Progression in Lung Adenocarcinoma.Cancer Res.2022 Oct 4;82(19):3516-3531.IF: 12.5

27. Lu L#, Zhang H#, Zhou Y, Lin J, Gao W, Yang T, Jin J, Zhang L, Nagle DG, ZhangW, Wu Y*,Chen H*, Luan X*. Polymer chimera of stapled oncolytic peptide coupledwith anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.Theranostics.2022 Apr 24;12(7):3456-3473.IF: 12.4

28. Zhang KR#, Zhang YF#, Lei HM, Tang YB, Ma CS, Lv QM, Wang SY, Lu LM, Shen Y,Chen HZ*, Zhu L*. Targeting AKR1B1 inhibits glutathione de novo synthesis toovercome acquired resistance to EGFR-targeted therapy in lung cancer.Sci TranslMed. 2021 Oct 6;13(614):eabg6428.IF: 15.8

29. Huang R#, Zhang L#, Jin J#, Zhou Y, Zhang H, Lv C, Lu D, Wu Y, Zhang H, Liu S,Chen H*, Luan X*, Zhang W*. Bruceine D inhibits HIF-1α-mediated glucosemetabolism in hepatocellular carcinoma by blocking ICAT/β-catenininteraction.Acta Pharm Sin B. 2021 Nov;11(11):3481-3492.IF: 14.8

30. Liu XL#, Dong X#, Yang SC, Lai X, Liu HJ, Gao Y, Feng HY, Zhu MH, Yuan Y, Lu Q,Lovell JF,Chen HZ*, Fang C*. Biomimetic Liposomal Nanoplatinum for TargetedCancer Chemophototherapy.Adv Sci (Weinh). 2021 Mar 1;8(8):2003679.IF: 14.3

31. Wang J#, Hu HJ#, Liu ZK, Liu JJ, Wang SS, Cheng Q,Chen HZ*, Song M*.Pharmacological inhibition of asparaginyl endopeptidase by δ-secretase inhibitor11 mitigates Alzheimer's disease-related pathologies in a senescence-acceleratedmouse model.Transl Neurodegener. 2021 Mar 31;10(1):12.IF: 10.8

32. Ni L#, Chen L#, Huang X, Han C, Xu J, Zhang H, Luan X, Zhao Y, Xu J, Yuan W*,Chen H*. Combating COVID-19 with integrated traditional Chinese and Westernmedicine in China.Acta Pharm Sin B. 2020 Jul;10(7):1149-1162.IF: 14.8

33. Jiang G#, Chen H#, Huang J, Song Q, Chen Y, Gu X, Jiang Z, Huang Y, Lin Y,Feng J, Jiang J, Bao Y, Zheng G, Chen J,Chen H*, Gao X*. Tailored Lipoprotein-Like miRNA Delivery Nanostructure Suppresses Glioma Stemness and Drug Resistancethrough Receptor-Stimulated Macropinocytosis.Adv Sci (Weinh). 2020 Jan20;7(5):1903290.IF: 14.3

34. Jin J#, Wu Y#, Chen J, Shen Y, Zhang L, Zhang H, Chen L, Yuan H,Chen H*, ZhangW*, Luan X*. The peptide PROTAC modality: a novel strategy for targeted proteinubiquitination.Theranostics. 2020 Aug 8;10(22):10141-10153.IF: 12.4

35. Huang K#, Liang Q#, Zhou Y#, Jiang LL, Gu WM, Luo MY, Tang YB, Wang Y, Lu W,Huang M, Zhang SZ, Zhuang GL, Dai Q, Shen QC, Zhang J, Lei HM, Zhu L, Ye DY,Chen HZ*, Zhou L*, Shen Y*. A Novel Allosteric Inhibitor of Phosphoglycerate Mutase1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer.Cell Metab.2019 Dec 3;30(6):1107-1119.e8.IF: 27.7